Fig. 22 (abstract P235).From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part twoIncreased M1/M2 ratio by combination therapy with TLR7 agonist and anti-PD-1 in HPV negative HNCBack to article page